Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).
Shingo Matsumoto(National Cancer Center Hospital East), Kōichi Goto(National Cancer Center Hospital East), Koji Takeda(NewYork–Presbyterian Hospital), Katsuya Tsuchihara(Chiba Cancer Center), Takashi Kohno(Gunma University), Haruyasu Murakami(Shizuoka Cancer Center), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Masato Shingyoji(Chiba Cancer Center), Eiji Iwama(Kyushu University), Genichiro Ishii(Juntendo University), Kiyotaka Yoh(National Cancer Center Hospital East), Takako Okuyama(Osaka International Cancer Institute), Takuma Yokoyama(Kyorin University Hospital), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Koji Tsuta(Kansai Medical University), Norio Okamoto(Osaka Prefectural Medical Center), Daijiro Harada(Shikoku Cancer Center)
Cited by 4
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k